Longeveron (LGVN) AI Stock Analysis

• Market Cap: $16.26M
• Dividend Yield: N/A
• Average Volume (3M): 473.11K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.54
• Revenue Growth: -22.41%
• EPS Growth: 78.88%
• Country: US
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 19,848,877
• 10 Day Avg. Volume: 706,553
• 30 Day Avg. Volume: 473,105
• PEG Ratio: 0.02
• Price to Book (P/B): 1.18
• Price to Sales (P/S): 10.77
• P/FCF Ratio: -1.73
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: 7.18
• Enterprise Value/Gross Profit: 9.59
• Enterprise Value/Ebitda: -0.50
• 1Y Price Target: $3.50
• Price Target Upside: 483.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $0.50 ▼(-16.67% Downside)

Longeveron's overall stock score reflects significant financial and operational challenges, with declining revenues and negative profitability being the most impactful factors. While technical indicators suggest oversold conditions, the company's valuation and financial outlook remain concerning. The earnings call highlights potential strategic advancements, but financial risks and the need for additional funding weigh heavily on the stock's prospects.

Positive Factors

Strong Pipeline and FDA Designations

The robust pipeline and multiple FDA designations suggest strong potential for future product approvals, enhancing long-term growth prospects and competitive positioning in the biotechnology industry.

Progress in HLHS Clinical Trial

Successful completion of the Phase IIb trial enrollment in HLHS indicates progress towards commercialization, potentially leading to new revenue streams and strengthening market position.

Positive Initial Results in Multiple Trials

Positive trial results across multiple indications suggest potential for future breakthroughs, enhancing the company's innovation capability and long-term growth potential in regenerative medicine.

Negative Factors

Revenue Decline

Significant revenue decline indicates challenges in maintaining market demand and financial stability, potentially impacting long-term sustainability and investment in R&D.

Increased Expenses and Net Loss

Rising expenses and net loss highlight operational inefficiencies and financial strain, which could limit the company's ability to invest in growth and innovation over the long term.

Financial Risks and Cash Runway Limitations

Limited cash runway and financial risks emphasize the need for additional funding, potentially leading to dilution or unfavorable financing terms, impacting long-term financial health.

Longeveron Business Overview & Revenue Model

Company Description

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

How the Company Makes Money

Longeveron generates revenue primarily through the development and commercialization of its cellular therapies. The company conducts clinical trials to advance its product candidates, which can lead to partnerships with larger pharmaceutical companies for further development and distribution. Additionally, Longeveron may receive funding through government grants or collaborations for research and development efforts. Key revenue streams include potential product sales from successful clinical trials, licensing agreements, and partnerships that may provide milestone payments and royalties based on future sales of its therapies.

Longeveron Financial Statement Overview

Summary

Longeveron faces significant financial challenges, with declining revenues, negative profitability, and cash flow issues. Despite low leverage, the inability to generate positive returns on equity and consistent negative cash flows highlight operational inefficiencies and financial instability.

Income Statement

Longeveron's income statement shows significant challenges, with declining revenue and negative profit margins. The TTM data reveals a revenue decrease of 30.68%, and the company has consistently reported negative net profit margins, with the TTM at -14.85%. Despite a relatively high gross profit margin of 74.88% in the TTM, the negative EBIT and EBITDA margins indicate operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet reflects a low debt-to-equity ratio of 0.065 in the TTM, suggesting conservative leverage. However, the return on equity is negative, indicating that the company is not generating profits from its equity base. The equity ratio is not provided, but the overall financial health appears weak due to the negative ROE and declining equity over time.

Cash Flow

Cash flow analysis shows some improvement, with a positive free cash flow growth rate of 16.72% in the TTM. However, the operating cash flow remains negative, and the operating cash flow to net income ratio is unfavorable at -3.39, indicating cash flow challenges. The free cash flow to net income ratio is slightly positive, suggesting some alignment between cash flow and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.44M	2.39M	709.00K	1.22M	1.31M	5.63M
Gross Profit	1.08M	1.88M	221.00K	497.00K	590.00K	1.83M
EBITDA	-20.52M	-15.56M	-20.08M	-17.15M	-16.13M	-2.93M
Net Income	-21.34M	-15.97M	-21.41M	-18.84M	-17.05M	-3.72M
Balance Sheet
Total Assets	15.56M	25.56M	12.08M	27.41M	42.77M	9.24M
Cash, Cash Equivalents and Short-Term Investments	9.24M	19.23M	5.36M	19.66M	35.04M	816.00K
Total Debt	983.00K	1.45M	2.04M	2.60M	3.14M	4.14M
Total Liabilities	5.59M	3.67M	5.34M	6.91M	5.31M	7.28M
Stockholders Equity	9.97M	21.89M	6.74M	20.50M	37.45M	1.96M
Cash Flow
Free Cash Flow	-16.98M	-14.86M	-19.30M	-14.82M	-10.95M	-2.63M
Operating Cash Flow	-16.72M	-13.87M	-19.00M	-13.97M	-9.64M	-2.36M
Investing Cash Flow	-654.00K	-640.00K	8.19M	-677.00K	-10.70M	-261.50K
Financing Cash Flow	3.84M	28.79M	5.26M	-509.00K	45.17M	1.58M

Longeveron Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LGVN, the sentiment is Negative. The current price of 0.6 is below the 20-day moving average (MA) of 0.76, below the 50-day MA of 0.78, and below the 200-day MA of 1.22, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 23.89 is Positive, neither overbought nor oversold. The STOCH value of 3.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LGVN.

Longeveron Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IBIO	43 Neutral	$24.51M	―	-54.50%	―	185.71%	79.03%
LGVN	43 Neutral	$16.26M	-0.58	-119.92%	―	-22.41%	78.88%
FBLG	38 Underperform	$16.83M	-0.68	-1292.87%	―	―	18.47%
EDSA	35 Underperform	$11.96M	-1.28	-69.64%	―	―	22.63%
CMMB	33 Underperform	$13.81M	-1.09	-120.76%	―	―	47.86%
PCSA	29 Underperform	$17.42M	-0.15	-270.74%	―	―	72.88%

Longeveron Corporate Events

Longeveron Announces Resignation of Board Members

On November 7, 2025, Longeveron Inc. announced the immediate resignation of Mr. Khoso Baluch and Ms. Neha Motwani from its Board of Directors. Their departures were not due to any disagreements with the company’s operations, policies, or management, suggesting a smooth transition without internal conflict.

The most recent analyst rating on (LGVN) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.

Longeveron Inc. Earnings Call: Mixed Sentiments Amid Clinical Progress

The recent earnings call for Longeveron Inc. painted a mixed picture of the company’s current standing and future prospects. While there were notable advancements in clinical trials and a robust pipeline buoyed by favorable FDA designations, the company is grappling with financial challenges. These include declining revenues, increased expenses, and potential delays in regulatory filings. To navigate these hurdles, Longeveron is actively seeking partnerships and additional funding.

Longeveron Inc. Reports Q3 2025 Financial Results

Longeveron Inc. is a clinical-stage biotechnology company based in Miami, Florida, focused on developing cellular therapies for aging-related and life-threatening conditions. The company operates within the biotechnology sector and is known for its innovative approach to addressing unmet medical needs.

Longeveron Appoints Dr. George Paletta to Board

On October 1, 2025, Longeveron Inc. announced the appointment of Dr. George Paletta to its Board of Directors. Dr. Paletta, an internationally recognized orthopedic surgeon and entrepreneur, brings extensive experience in medicine and business to the company. His appointment comes at a pivotal time for Longeveron as it advances its stem cell therapy pipeline, including a pivotal clinical trial in hypoplastic left heart syndrome with data expected in 2026. This strategic addition is expected to enhance Longeveron’s efforts in commercializing stem cell therapies, benefiting healthcare, patients, and shareholders.

The most recent analyst rating on (LGVN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.

Longeveron Faces Nasdaq Delisting Notice for Stock Price

On September 22, 2025, Longeveron Inc. received a notice from Nasdaq indicating that its Class A common stock failed to meet the $1.00 minimum bid price requirement for continued listing. The company has until March 23, 2026, to regain compliance by ensuring the bid price closes at $1.00 or more for at least ten consecutive business days. If compliance is not achieved, Longeveron may face delisting or seek an additional compliance period while assessing options to rectify the deficiency.

The most recent analyst rating on (LGVN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.

Longeveron Announces Leadership Changes Amidst CEO Departure

On August 27, 2025, Longeveron Inc. announced a leadership change with CEO Wa’el Hashad stepping down to pursue other opportunities. Than Powell, the current Chief Business Officer, was appointed as interim CEO effective September 4, 2025. Dr. Joshua Hare, the company’s founder and Chief Science Officer, was appointed as Executive Chairman of the Board. This transition occurs as Longeveron continues to advance its stem cell therapy pipeline, with pivotal Phase 2b clinical trials underway for laromestrocel, and plans for a national search to identify a permanent CEO. The company remains focused on leveraging its stem cell technology to benefit patients and shareholders.

The most recent analyst rating on (LGVN) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.

Longeveron Inc. Earnings Call: Progress Amid Challenges

Longeveron Inc.’s recent earnings call painted a mixed picture, highlighting significant strides in clinical trials and pipeline expansion, while also acknowledging challenges such as declining revenue and rising expenses. The sentiment was cautiously optimistic, with strategic moves in manufacturing and financial planning being tempered by regulatory and financial uncertainties.

Longeveron Inc. Faces Regulatory and Manufacturing Challenges Threatening Financial Stability

Longeveron Inc. faces significant business risks related to its CMC readiness and manufacturing capabilities for commercialization, which may experience delays or be unsuccessful. The complexity of BLA-enabling activities, such as comparability protocols and process validation, coupled with regulatory scrutiny, poses challenges that could impede the company’s ability to meet regulatory and investor expectations for product approval and launch. The FDA’s discretionary power and the uncertain, costly approval process further exacerbate these risks, potentially affecting the clinical and commercial success of Longeveron’s product candidates. Consequently, any setbacks in completing CMC readiness and BLA-enabling activities could materially harm Longeveron’s financial condition.

Longeveron Inc. Reports Q2 2025 Financial Results

Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines for life-threatening, rare pediatric, and chronic aging-related conditions. The company recently announced its second quarter 2025 financial results and provided a business update, highlighting significant progress in its clinical trials and strategic initiatives.